These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32829322)

  • 21. Reduction of a marker of oxidative stress with enhancement of iron utilization by erythropoiesis activation following epoetin beta pegol administration in iron-loaded db/db mice.
    Noguchi-Sasaki M; Sasaki Y; Matsuo-Tezuka Y; Yasuno H; Kurasawa M; Yorozu K; Shimonaka Y
    Int J Hematol; 2016 Mar; 103(3):262-73. PubMed ID: 26739261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twice-monthly administration of a lower dose of epoetin beta pegol can maintain adequate hemoglobin levels in hemodialysis patients.
    Morikami Y; Fujimori A; Okada S; Kumei M; Mizobuchi N; Sakai M
    Ther Apher Dial; 2015 Apr; 19(2):138-43. PubMed ID: 25402974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study.
    Dellanna F; Winkler RE; Bozkurt F; Schettler V; Graf S; Bockreiss N; Fliser D;
    Int J Clin Pract; 2011 Jan; 65(1):64-72. PubMed ID: 21091595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
    Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
    Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erythropoiesis equivalence, pharmacokinetics and immune response following repeat hematide administration in cynomolgus monkeys.
    Woodburn KW; Schatz PJ; Fong KL; Beaumier P
    Int J Immunopathol Pharmacol; 2010; 23(1):121-9. PubMed ID: 20378000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
    Pashos CL; Larholt K; Fraser KA; McKenzie RS; Senbetta M; Piech CT
    Support Care Cancer; 2012 Jan; 20(1):159-65. PubMed ID: 21359879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients.
    Hahn D; Esezobor CI; Elserafy N; Webster AC; Hodson EM
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011690. PubMed ID: 28066881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients.
    Washida N; Inoue S; Kasai T; Shinozuka K; Hosoya K; Morimoto K; Wakino S; Hayashi K; Itoh H
    Ther Apher Dial; 2015 Oct; 19(5):450-6. PubMed ID: 25944557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
    Tsuruya K; Hayashi T; Yamamoto H; Hase H; Nishi S; Yamagata K; Nangaku M; Wada T; Uemura Y; Ohashi Y; Hirakata H;
    Clin Exp Nephrol; 2021 May; 25(5):456-466. PubMed ID: 33411115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.
    Hörl WH
    Drugs; 2013 Feb; 73(2):117-30. PubMed ID: 23338536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
    Canaud B; Mingardi G; Braun J; Aljama P; Kerr PG; Locatelli F; Villa G; Van Vlem B; McMahon AW; Kerloëguen C; Beyer U;
    Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients.
    Kuwahara M; Arai Y; Takehara E; Sasaki Y; Yoshimine T; Kusaka K; Shikuma S; Akita W; Uchida S
    Clin Exp Nephrol; 2016 Aug; 20(4):585-594. PubMed ID: 26511877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
    Yoshida T; Hayashi M
    Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease.
    Mann JF; de Francisco A; Nassar G; Canaud B
    Clin Nephrol; 2011 Jul; 76(1):9-15. PubMed ID: 21722600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study.
    Sánchez-Fructuoso AI; Ruiz JC; Torregrosa JV; González E; Gómez E; Gallego RJ; Troya MI; Jimenez C; Llamas F; Romero R; Bernis C; Crespo JF; Guirado L;
    Adv Ther; 2012 Nov; 29(11):979-91. PubMed ID: 23160946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-acting erythropoiesis-stimulating agent (ESA) induces physiological erythropoiesis via improvement of iron availability.
    Masumoto M; Kuragano T; Takata C; Fukui R; Mihara Y; Okamoto R; Iwasaki T; Ookawa S; Aichi M; Yahiro M; Kida A; Nanami M
    Int Urol Nephrol; 2022 May; 54(5):1079-1084. PubMed ID: 34390438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.